COVID-19 studies for: C19 studies:  HC QHC Q IvermectinIVM Vitamin DVitamin D ZincZn REGN-COV2REGN LY-CoVLY RemdesivirRMD
HC Q study #123
Source   PDF   Share   Tweet
See all 181 studies
9/9
Inconc.
Early, Late
Kirenga et al., BMJ Open Respiratory Research, doi:10.1136/bmjresp-2020-000646 (Peer Reviewed)
Characteristics and outcomes of admitted patients infected with SARS-CoV-2 in Uganda
Prospective 56 patients in Uganda, 29 HC Q and 27 control, showing 25.6% faster recovery with HC Q, 6.4 vs. 8.6 days (p = 0.20). There was no ICU admission, mechanical ventilation, or death.
Treatment delay is not specified but at least a portion of patients appear to have been treated early.
recovery time, ↓25.6%, p=0.20, median time to recovery
Source   PDF   Share   Tweet
See all 181 studies
Please send us corrections, updates, or comments.
Submit